PanACEA - STEP2C -01

• Status: Not yet recruiting
• Trial end date: 2025-02-23
• Target enrollment: 0
• Participant gender: All

Summary

This is a phase 2B/C, open label platform study that will compare the efficacy, safety of 3 experimental regimens with a standard control regimen in participants with newly diagnosed, drug sensitive pulmonary tuberculosis. In stage 1, participants will be randomly allocated to the control or one of the 2 rifampicin-containing experimental regimens in the ratio 1:1:1. In stage 2, the experimental arm 4 containing sutezolid will be added. Participants will be allocated to control or one of the three experimental regimens in the ratio 1:1:1:1. Towards the end of stage 2, when experimental arms 1 and 2 will be fully enrolled, participants will be randomized 1:1 to control and experimental arm 4. The objective is to evaluate the efficacy, safety, and tolerability of increased dose of rifampicin, an optimized dose of pyrazinamide, moxifloxacin, and sutezolid, in adult subjects with newly diagnosed, smear-positive pulmonary tuberculosis.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Michael Hoelscher
• Collaborators: Radboud University Medical Center; University College, London; University of California, San Francisco
• Treatments: Bedaquiline; Isoniazid; Moxifloxacin; Pyrazinamide; Rifampin

Criteria

Inclusion Criteria:

1. Provide written, informed consent prior to all trial-related procedures including HIV testing.

2. Male or female, aged between 18 and 65 years, inclusive.

3. Body weight (in light clothing and with no shoes) between 40 and 90 kg, inclusive.

4. Newly diagnosed, previously untreated, drug susceptible pulmonary TB: presence of MTB complex and rapid molecular tests result confirming susceptibility to RIF and INH such as GeneXpert and/or HAIN MTBDR plus.

5. A chest X-ray (no older than 2 weeks) which, in the opinion of the Investigator, is consistent with TB.

6. Sputum positive on microscopy from concentrated sputum for acid-fast bacilli on at least one sputum sample (at least 1+ on the IUATLD/WHO scale).

7. The participant understands the interaction between the study drugs and certain foods and is willing to forgo the consumption of foods high in tyramine for the period of study medication, which will be necessary if randomized to arm 4 (See Appendix, section 20.2, page 92).

8. The participant is not of child-bearing potential or is willing to use effective methods of contraception when engaging in heterosexual intercourse, as defined below:

1. Non-childbearing potential: i. Female participant/sexual partner of male participant: Bilateral oophorectomy, and/or hysterectomy or bilateral tubal ligation more than 12 months ago and/or has been postmenopausal with a history of no menses for at least 12 consecutive months ii. Male participant/sexual partner of female participant: Vasectomised or has had a bilateral orchidectomy minimally three months prior to screening seen prior to 76 weeks after randomization iii. Male participants having a pregnant female partner or a male sexual partner: At least one barrier method has to be used in this case.

2. Effective contraception methods: i. Female participants: Two methods, including methods that the participant's sexual partner(s) use. At least one must be a barrier method. Contraception must be practised for at least until 12 weeks after the last dose of experimental treatment. ii. Male participants: Two methods, including methods that the participant's female sexual partner(s) use. At least one must be a barrier method. Effective contraception must be ensured for at least 16 weeks after the last dose of experimental treatment.

Exclusion Criteria:

1. Circumstances that raise doubt about free, unconstrained consent to study participation (e.g., prisoner or mentally handicapped person)

2. Poor general condition where delay in treatment cannot be tolerated or death within four months is likely.

3. Poor social condition which would make it unlikely that the participant would be able to complete follow-up:

4. The participant is pregnant or breast-feeding or planning to become pregnant in the study period.

5. The participant is infected with HIV with a CD4 count <220 cells/mm3. If >22 cells/mm3 participants will be included only if any of the following is applicable:

• The participant is antiretroviral (ARV) naïve and able to postpone commencing HIV treatment for 2 months after the trial has started and then restrict regimens to those mentioned in section on ARVs Antiretroviral Therapy or

• The participant is ARV experienced (has been on ARV´s a minimum of 5 months), AND:

ARV treatment is compliant to, or can be modified as described in the section on Antiretroviral Therapy

6. The participant has a known intolerance to any of the study drugs or concomitant disorders or conditions for which study drugs or standard TB treatment are contraindicated.

7. The participant has a history of, or current evidence of clinically relevant cardiovascular metabolic, gastrointestinal, neurological, psychiatric or endocrine diseases, malignancy, or any other condition that will influence treatment response, study adherence or survival in the judgement of the investigator, especially:

1. Neuropathy, or significant psychiatric disorder like depression or schizophrenia; especially if treatment for those has ever been required or is anticipated to be required.

2. Evidence of clinically significant extra-pulmonary TB (e.g. miliary TB, TB meningitis, but not limited lymph node involvement).

3. Serious lung conditions other than TB, or significant respiratory impairment in the discretion of the investigator.

4. Uncontrolled diabetes mellitus.

5. Cardiovascular disease such as myocardial infarction, heart failure, coronary heart disease, arrhythmia, tachyarrhythmia, or pulmonary hypertension

6. Uncontrolled arterial hypertension (systolic blood pressure ≥150 mmHg and/or diastolic blood pressure of ≥95 mmHg on two occasions during screening).

7. Long QT syndrome or family history of long QT syndrome or family history of sudden death of unknown or cardiac-related cause

8. Alcohol, regular opiate, or other drug abuse that is sufficient to significantly compromise the safety or cooperation of the participant, that includes substances prohibited by the protocol or has led to significant organ damage at the discretion of the investigator.

8. Any of the following laboratory findings at screening:

1. Serum amino aspartate transferase (AST) and/or alanine aminotransferase (ALT) >3x the upper limit of normal (ULN),

2. Serum alkaline phosphatase or y-glutamyl transferase > 2.5x the ULN,

3. Serum total bilirubin level >1.5x the ULN

4. Estimated creatinine clearance (eCrCl; using the Cockroft and Gault formula [57] lower than 30 ml/min)

5. Serum albumin < 2.8 mg/dl

6. Haemoglobin level <7.0 g/dl

7. Platelet count <50,000/mm3

8. Serum potassium below the lower level of normal for the laboratory

9. ECG findings in the screening ECG: (one or more):

1. QTcF of >0.450 s

2. Atrioventricular (AV) block with PR interval > 0.20 s,

3. QRS complex > 120 milliseconds

4. Any other changes in the ECG that are clinically relevant as per discretion of the investigator

10. Restricted medication:

1. Treatment with any other investigational drug within 1 month prior to enrolment or enrolment into other clinical (intervention) trials during participation.

2. Previous anti-TB treatment with drugs active against MTB within the last 3 months prior to screening.

3. Unable or unwilling to abide by the requirements regarding restricted medication or have taken restricted medication. Restricted medication includes the following drug classes, with relevant timing of intake. Exceptions may be permissible after discussion with the sponsor medical expert. Anti-TB drugs other than study drugs Medication that increases the risk for serious cardiac arrhythmia (see 8.5.4). Drugs that affect monoamine oxidase or serotonin metabolism CYP 450 inhibitors or inducers.